At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RYTM Rhythm Pharmaceuticals Inc.
Pre-Mkt 03-18 06:48:37 EDT
87.68
-2.83
-3.13%
盘前89.35
+1.67+1.90%
06:47 EDT
High91.05Low86.81Vol1.03M
Open89.29D1 Closing90.51Amplitude4.69%
Mkt Cap5.99BTradable Cap4.86BTotal Shares68.29M
T/O91.29MT/O Rate1.86%Tradable Shares55.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Rhythm price target lowered to $100 from $110 at H.C. Wainwright
TIPRANKS  ·  38 minutes ago
Rhythm price target lowered to $100 from $110 at H.C. Wainwright
Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $100 From $110
THOMSON REUTERS  ·  40 minutes ago
Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $100 From $110
U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks
Reuters  ·  15:36
U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks
These Stocks Are Today's Movers: Nvidia, Oklo, Delta, Carnival, Uber, Honeywell, Elbit, and More -- Barrons.com
Dow Jones  ·  03-17 20:51
These Stocks Are Today's Movers: Nvidia, Oklo, Delta, Carnival, Uber, Honeywell, Elbit, and More -- Barrons.com
Rhythm Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $136 From $142
THOMSON REUTERS  ·  03-17 19:32
Rhythm Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $136 From $142
Rhythm Pharmaceuticals Is Maintained at Buy by Needham
Dow Jones  ·  03-17 19:21
Rhythm Pharmaceuticals Is Maintained at Buy by Needham
Guggenheim Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
TIPRANKS  ·  03-17 19:15
Guggenheim Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK)
TIPRANKS  ·  03-17 19:10
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK)
RBC Lowers Price Target on Rhythm Pharmaceuticals to $130 From $140, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  03-17 18:31
RBC Lowers Price Target on Rhythm Pharmaceuticals to $130 From $140, Keeps Outperform, Speculative Risk
Rhythm Pharmaceuticals Inc : Needham Cuts Target Price to $130 From $139
THOMSON REUTERS  ·  03-17 18:00
Rhythm Pharmaceuticals Inc : Needham Cuts Target Price to $130 From $139
Rhythm Pharmaceuticals price target lowered to $152 from $176 at Citizens
TIPRANKS  ·  03-17 17:45
Rhythm Pharmaceuticals price target lowered to $152 from $176 at Citizens
Rhythm Pharmaceuticals Inc : RBC Cuts Target Price to $130 From $140
THOMSON REUTERS  ·  03-17 12:15
Rhythm Pharmaceuticals Inc : RBC Cuts Target Price to $130 From $140
Stocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura
Dow Jones  ·  03-17 07:12
Stocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura
BRIEF-Rhythm Pharmaceuticals Announces Topline Results From Phase 3 Emanate Trial
Reuters  ·  03-17 04:58
BRIEF-Rhythm Pharmaceuticals Announces Topline Results From Phase 3 Emanate Trial
Rhythm Pharma Exec Says the 2022‑Launched Trial Was Partly Affected by the Rise of Glp‑1 Drugs, Which May Have Contributed to High Patient Dropout Rates
THOMSON REUTERS  ·  03-17 04:47
Rhythm Pharma Exec Says the 2022‑Launched Trial Was Partly Affected by the Rise of Glp‑1 Drugs, Which May Have Contributed to High Patient Dropout Rates
Rhythm Pharma Exec Says Most Placebo Patients Stopped Treatment by Choice, While Most Setmelanotide Patients Discontinued Because of Side Effects
THOMSON REUTERS  ·  03-17 04:47
Rhythm Pharma Exec Says Most Placebo Patients Stopped Treatment by Choice, While Most Setmelanotide Patients Discontinued Because of Side Effects
Rhythm Pharma Exec Says Emanate Trail Saw an Avg 40% to 60% Patient Dropout Rate Across All Groups - Conf Call
THOMSON REUTERS  ·  03-17 04:47
Rhythm Pharma Exec Says Emanate Trail Saw an Avg 40% to 60% Patient Dropout Rate Across All Groups - Conf Call
Rhythm reports EMANATE trial substudies did not meet primary endpoints
TIPRANKS  ·  03-17 04:15
Rhythm reports EMANATE trial substudies did not meet primary endpoints
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
Reuters  ·  03-17 04:05
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
Rhythm Pharmaceuticals Shares Fall About 13% to $78.58 After the Bell Following Announcement That Emanate Phase 3 Trial Didn't Meet Primary Endpoints
THOMSON REUTERS  ·  03-17 04:04
Rhythm Pharmaceuticals Shares Fall About 13% to $78.58 After the Bell Following Announcement That Emanate Phase 3 Trial Didn't Meet Primary Endpoints

Introduction

Company Name.
Rhythm Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Issue price:
--